Explore

Trendline Trendline
Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments
Trendline Trendline
EyePoint Pharmaceuticals Reports Q1 2026 Financial Results Amid Clinical Progress

EyePoint Pharmaceuticals Reports Q1 2026 Financial Results Amid Clinical Progress

EyePoint Pharmaceuticals Reports Q1 2026 Financial Results Amid Clinical Progress
Trendline Trendline
EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding

EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding

EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding
Trendline Trendline
GSK Licenses siRNA Drug from China's SiranBio in $1 Billion Deal to Target Cardiometabolic Diseases

GSK Licenses siRNA Drug from China's SiranBio in $1 Billion Deal to Target Cardiometabolic Diseases

GSK Licenses siRNA Drug from China's SiranBio in $1 Billion Deal to Target Cardiometabolic Diseases
Trendline Trendline
EyePoint Reports Q1 2026 Financial Results, Highlights Progress in Retinal Disease Trials

EyePoint Reports Q1 2026 Financial Results, Highlights Progress in Retinal Disease Trials

EyePoint Reports Q1 2026 Financial Results, Highlights Progress in Retinal Disease Trials
Trendline Trendline
EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies

EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies

EyePoint Reports Q1 2026 Financial Results and Advances in Retinal Disease Therapies
Trendline Trendline
Amylyx Pharmaceuticals Reports Q1 2026 Financial Results, Advances Clinical Trials

Amylyx Pharmaceuticals Reports Q1 2026 Financial Results, Advances Clinical Trials

Amylyx Pharmaceuticals Reports Q1 2026 Financial Results, Advances Clinical Trials
Trendline Trendline
Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine

Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine

Sarepta Therapeutics Reports Strong Q1 2026 Financial Results and Advances in Genetic Medicine
Trendline Trendline
Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments

Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments

Exelixis Reports Q1 2026 Financial Results and Announces New Drug Developments
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark

Summit Shares Plummet as Cancer Drug Fails Early Survival Benchmark
Trendline Trendline
Cryoport Reports Strong Q1 2026 Financial Results with Revenue Growth

Cryoport Reports Strong Q1 2026 Financial Results with Revenue Growth

Cryoport Reports Strong Q1 2026 Financial Results with Revenue Growth